Enovis Corp
NYSE:ENOV
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
38.72
63.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Enovis Corp
Enovis Corp
Cash & Cash Equivalents
Enovis Corp
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Enovis Corp
NYSE:ENOV
|
Cash & Cash Equivalents
$36.2m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Cash & Cash Equivalents
$1.7B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
26%
|
CAGR 10-Years
-1%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash & Cash Equivalents
$2.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
55%
|
CAGR 10-Years
26%
|
|
|
Stryker Corp
NYSE:SYK
|
Cash & Cash Equivalents
$3.9B
|
CAGR 3-Years
15%
|
CAGR 5-Years
15%
|
CAGR 10-Years
11%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Cash & Cash Equivalents
$7B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash & Cash Equivalents
$2.4B
|
CAGR 3-Years
21%
|
CAGR 5-Years
20%
|
CAGR 10-Years
17%
|
|
Enovis Corp
Glance View
Enovis Corp is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Wilmington, Delaware and currently employs 16,200 full-time employees. The company went IPO on 2008-05-08. Enovis Corporation, formerly Colfax Corporation, is a medical technology company that provides orthopedic care and fabrication technology products and services under DJO brand. The Company’s segments include Fabrication Technology and Medical Technology. The Fabrication Technology segment formulates, develops, manufactures and supplies consumable products and equipment, including cutting, joining, and automated welding products, as well as gas control equipment. Its fabrication technology products are marketed under several brands. The Medical Technology segment develops, manufactures and distributes medical devices and services across the continuum of patient care from injury prevention to joint replacement to the rehabilitation after surgery, injury from degenerative disease, enabling people to regain or maintain their natural motion. Its products are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, and others.
See Also
What is Enovis Corp's Cash & Cash Equivalents?
Cash & Cash Equivalents
36.2m
USD
Based on the financial report for Dec 31, 2023, Enovis Corp's Cash & Cash Equivalents amounts to 36.2m USD.
What is Enovis Corp's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-14%
Over the last year, the Cash & Cash Equivalents growth was 49%. The average annual Cash & Cash Equivalents growth rates for Enovis Corp have been -28% over the past three years , -14% over the past five years .
You don't have any saved screeners yet
